Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 5/20 | 0.35 |
| ▸ | TPH2 | Q8IWU9 | 5/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5373684 | 0.84 | — | — | |
| SCHEMBL5377324 | 0.81 | KDM1A (0.36) | HPGDHSD17B10 | |
| SCHEMBL5385628 | 0.79 | WDR5 (0.35) | TP53HPGDHSD17B10 | |
| SCHEMBL5373744 | 0.77 | — | — | |
| SCHEMBL5372902 | 0.77 | PDE10A (0.36) | HPGD | |
| SCHEMBL5365172 | 0.74 | — | — | |
| SCHEMBL5382083 | 0.74 | — | — | |
| SCHEMBL5386352 | 0.73 | NR4A2 (0.31) | — | |
| SCHEMBL5365189 | 0.73 | — | — | |
| SCHEMBL5371212 | 0.73 | HCAR2 (0.42) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232582-A1 | 4-substituted or unsubtituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-10-04 | — | — | US | disclosed |
| US-7229983-B2 | 4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as β-lactamase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2007-06-12 | — | — | US | disclosed |
| US-20040214812-A1 | 4-Substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | WYETH HOLDINGS CORPORATION (US) | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214812-A1 | 4-Substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | DDC, AADAC, ALDH7A1 | TPH1 1498/4885TPH2 2434/4885TP53 4278/4885 |
| US-20070232582-A1 | 4-substituted or unsubtituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid derivatives as beta-lactamase inhibitors | DDC, AADAC, ALDH7A1 | TPH1 923/4885TPH2 2168/4885TP53 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.